Ignite Creation Date:
2024-05-06 @ 7:05 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05880316
Status:
RECRUITING
Last Update Posted:
2023-05-30
First Post:
2023-05-10
Brief Title:
Prevalence of MAFLD Among Nurses and the Role of Intermittent Fasting
Sponsor:
Universiti Kebangsaan Malaysia Medical Centre
Organization:
Universiti Kebangsaan Malaysia Medical Centre
Study Overview
Official Title:
Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease MAFLD Among Nurses in a Single Tertiary Care Centre and the Role of Intermittent Fasting in Improving Hepatic Steatosis
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study consists of 2 parts
Part 1 a cross-sectional study looking at the prevalence of metabolic dysfunction-associated fatty liver disease MAFLD among nurses in Hospital Canselor Tuanku Muhriz HCTM
Part 2 a randomized controlled trial of intermittent fasting with MAFLD subjects
Part 1 a cross-sectional study looking at the prevalence of metabolic dysfunction-associated fatty liver disease MAFLD among nurses in Hospital Canselor Tuanku Muhriz HCTM
Part 2 a randomized controlled trial of intermittent fasting with MAFLD subjects
Detailed Description:
The investigators aim to screen at least 350 participants for fibroscan-detected fatty liver Baseline anthropometric data will be taken Questionnaires on dietary habits - Foof Frequency Questionnaire FFQ and exercise habits - International Physical Activity Questionnaire IPAQ will be done
Approximately 100 participants who have fatty liver from Part 1 study will be enrolled and randomized into Part 2 The intervention group will undergo intermittent fasting 3 fasting day4 non-fasting days while the control group will continue the usual standard care for 8 weeks
Measurements pre- and post-intervention include Fibroscan measurement blood LiverFASt anthropometric data and exercise habit IPAQ
Approximately 100 participants who have fatty liver from Part 1 study will be enrolled and randomized into Part 2 The intervention group will undergo intermittent fasting 3 fasting day4 non-fasting days while the control group will continue the usual standard care for 8 weeks
Measurements pre- and post-intervention include Fibroscan measurement blood LiverFASt anthropometric data and exercise habit IPAQ
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None